Komabashiri Naohiro, Suehiro Fumio, Ishii Masakazu, Nishimura Masahiro
Department of Oral and Maxillofacial Prosthodontics, Kagoshima University Graduate School of Medical and Dental Science, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
Regen Ther. 2021 Mar 27;18:38-50. doi: 10.1016/j.reth.2021.03.004. eCollection 2021 Dec.
Maxillary/mandibular bone marrow stromal cells (MBMSCs) are a useful cell source for bone regeneration in the oral and maxillofacial region. To further ensure the clinical application of MBMSCs in bone regenerative therapy, it is important to determine the bone formation capacity of MBMSCs before transplantation. The aim of this study is to identify the molecular marker that determines the bone formation capacity of MBMSCs.
The cell growth, cell surface antigens, and bone formation capacity of MBMSCs were examined. The amount of chitinase-3-like protein 1 (CHI3L1) secreted into the conditioned medium was quantified. The effects of CHI3L1 on the cell growth and osteogenic differentiation potential of MBMSCs and on the cell growth and migration of vascular endothelial cells and fibroblasts were examined.
The cell growth, and and bone formation capacity of the cells treated with different conditions were observed. MBMSCs that secreted a large amount of CHI3L1 into the conditioned medium tended to have low bone formation capacity, whereas MBMSCs that secreted a small amount of CHI3L1 had greater bone formation capacity. CHI3L1 promoted the migration of vascular endothelial cells, and the cell growth and migration of fibroblasts.
Our study indicates that the osteogenic differentiation capacity of MBMSCs and the bone formation capacities of MBMSCs were not necessarily correlated. The transplantation of high CHI3L1 secretory MBMSCs may suppress bone formation by inducing fibrosis at the site. These results suggest that the CHI3L1 secretion levels from MBMSCs may be used as a predictable marker of bone formation capacity .
上颌/下颌骨髓基质细胞（MBMSCs）是口腔颌面区域骨再生的一种有用细胞来源。为进一步确保MBMSCs在骨再生治疗中的临床应用，在移植前确定MBMSCs的骨形成能力很重要。本研究的目的是鉴定决定MBMSCs骨形成能力的分子标志物。
检测了MBMSCs的细胞生长、细胞表面抗原和骨形成能力。对条件培养基中分泌的几丁质酶-3样蛋白1（CHI3L1）的量进行了定量。研究了CHI3L1对MBMSCs的细胞生长和成骨分化潜能以及对血管内皮细胞和成纤维细胞的细胞生长和迁移的影响。
观察了不同条件处理的细胞的细胞生长和骨形成能力。向条件培养基中分泌大量CHI3L1的MBMSCs往往骨形成能力较低，而分泌少量CHI3L1的MBMSCs骨形成能力较强。CHI3L1促进了血管内皮细胞的迁移以及成纤维细胞的细胞生长和迁移。
我们的研究表明，MBMSCs的成骨分化能力与MBMSCs的骨形成能力不一定相关。高CHI3L1分泌型MBMSCs的移植可能通过诱导局部纤维化来抑制骨形成。这些结果表明，MBMSCs的CHI3L1分泌水平可作为骨形成能力的一个可预测标志物。
